2017
DOI: 10.1002/chem.201700936
|View full text |Cite
|
Sign up to set email alerts
|

Organic CO Prodrugs: Structure–CO‐Release Rate Relationship Studies

Abstract: Carbon monoxide (CO) is an endogenously produced gasotransmitter in mammals, and may have signaling roles in bacteria as well. It has many recognized therapeutic effects. A significant challenge in this field is the development of pharmaceutically acceptable forms of CO delivery with controllable and tunable release rates. Herein, we describe the structure-release rate studies of the first class of organic CO-prodrugs that release CO in aqueous solution at neutral pH.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
52
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 66 publications
(53 citation statements)
references
References 60 publications
1
52
0
Order By: Relevance
“…Therefore, novel water-soluble CO delivery molecules were described, tricarbonylchloro (glycinato) ruthenium II (RuCl(glycinato)(CO) 3 ), termed CORM-3; boron-based compound Na 2 H 3 BCO 2 , named CORM-A1; or recently developed CORM-401 (Mn(CO) 4 [43]) that in contrast to CORM-A1 releases up to three equivalents of CO per mol of the compound [42][43][44]. Additionally, the new class of organic CO-releasing prodrugs was developed recently [42,[45][46][47]. These CO prodrugs do not contain heavy metals, have a long half-life, and are able to release CO in a controllable manner.…”
Section: Carbon Monoxide Deliverymentioning
confidence: 99%
“…Therefore, novel water-soluble CO delivery molecules were described, tricarbonylchloro (glycinato) ruthenium II (RuCl(glycinato)(CO) 3 ), termed CORM-3; boron-based compound Na 2 H 3 BCO 2 , named CORM-A1; or recently developed CORM-401 (Mn(CO) 4 [43]) that in contrast to CORM-A1 releases up to three equivalents of CO per mol of the compound [42][43][44]. Additionally, the new class of organic CO-releasing prodrugs was developed recently [42,[45][46][47]. These CO prodrugs do not contain heavy metals, have a long half-life, and are able to release CO in a controllable manner.…”
Section: Carbon Monoxide Deliverymentioning
confidence: 99%
“…Wang and co‐workers have explored the development of organic prodrugs that undergo cheletropic reaction under physiologically relevant conditions to spontaneously release CO ,. These generally non‐toxic molecules (up to 100 μM) are designed to undergo inter‐ or intra‐molecular inverse electron demand Diels‐Alder (DA inv ) reactions with tunable CO release rates.…”
Section: Fluorescence Trackable Metal‐free Co‐releasing Molecules or mentioning
confidence: 99%
“…[24] The derivatives BW-CO-109 and BW-CO-117 were subsequently shown to exhibit a concentration-dependent increase in fluorescence intensity for CO delivery in RAW 264.7 cells. [36] A cascade drug delivery system (23, Figure 21) has also been developed on this premise wherein a drug payload (metronidazole) is released along with CO and a fluoranthene by-product. The latter provides visual evidence of the release of all three molecules.…”
Section: Click and Release Corms: Intra-and Inter-molecular Inverse Ementioning
confidence: 99%
See 1 more Smart Citation
“…The design for controlled CO release centers on conformational constraints, with an ester bond holding an alkyne dienophile away from a dienone. Upon cleavage of the ester bond by an esterase, the freed dienophile undergoes an entropically favored intramolecular Diels–Alder cycloaddition to release CO (Figure e; Ji et al, ; Pan et al, ). Proof‐of‐concept compounds readily release CO in the presence of PLE and give only the expected cyclization products in their respective reactions, suggesting that the enzyme‐catalyzed hydrolysis is the rate limiting step.…”
Section: Esterase‐activated Prodrugsmentioning
confidence: 99%